Cancer Throughlines: Almost 20 Years On, HPV Vaccine Still Surpasses Expectations Available to Purchase

Since its approval in 2006, the human papillomavirus (HPV) vaccine has played an instrumental role in reducing HPV infection and cervical cancer incidence. Despite the overwhelming evidence of its superior efficacy and safety from clinical trials and long-term studies, the vaccine has recently been subject to skepticism.